Court Favors Boehringer In Third Pradaxa Bellwether Trial
Court Favors Boehringer In Third Pradaxa Bellwether Trial
Introduction
A Hartford Superior Court ruled in favor of Boehringer Ingelheim Pharmaceuticals in the third bellwether trial involving claims by a man who suffered bleeding due to the alleged use of blood thinner medication Pradaxa.
The trial for claims brought by the plaintiff in 2016 concluded after a three-week deliberation, and it is the third straight win for Boehringer. The first two trials held in March 2018 and May 2018 also ended in a defense verdict. The next bellwether trial involving claims of health hazards of Pradaxa will begin in February 2019.
Pradaxa was initially approved by the U.S. FDA to be used as a blood thinner, but reports suggest it causes serious injuries and gastrointestinal bleeding, heart attack, stroke, brain hemorrhage, kidney bleeding, and death. Judge Herndon, who overlooked Pradaxa class action lawsuits, recommended a shutdown of the multidistrict litigation (MDL No. 2385) in December 2017 after dismissing pending cases in the docket.
Comments
Latest News
Walgreens Settles Federal Opioid Case for $300 Million
Categories: Opioids
Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.
The U.S. Department of Justice announced on Monday…
Study: Opioid Use in Pregnancy May Shrink Newborn Brains
Categories: Opioids
New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…
Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting
Categories: Opioids
The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…